Schroders trust rebalances away from Woodford portfolio with third fresh private holding
Woodford Patient Capital Trust was handed to Schroders almost two years ago
Neil Woodford
-
-
Acacia pockets £16m from partial sale of former Woodford Oxford Nanopore stake
Share sale combined with value of US investor’s remaining stake represents a 78% uplift on biotech firm’s last valuation
-
Woodford case goes to court as Leigh Day triggers proceedings against Link
Claim involves initial group of 100 former Woodford Equity Income investors
-
Schroders swaps out co-manager on former Woodford trust
Ben Wicks will step down from Schroder UK Public Private effective immediately
-
Schroders trust welcomes Oxford Nanopore listing but expects to sell down 3.7% stake
Oxford Nanopore represented 21.8% of SUPP’s net asset value on 31 March
-
Former Woodford dud sees fortunes climb on controversial approval of Alzheimer’s drug
Prothena’s share price has spiked 484% this year
-
Schroders trust unveils second fresh holding since Woodford takeover
SUPP is currently trading on a 20% discount
-
Execs at Woodford darling Oxford Nanopore set for bumper £160m payday
DNA sequencing unicorn reported a £73m pre-tax loss in 2020 despite revenue boost from government contracts for Covid tests
-
Is Link doing enough with Woodford investors still in limbo?
‘Arguably they [Link] should have taken more time selling some of the earlier holdings’
-
Woodford investors face longer wait times as Link struggles to ditch illiquid biotech names
Benevolent AI and Atom Bank among the £124m in assets left to be sold
-
Specialist private client firm ploughs £4.3m into Mark Barnett’s unquoteds purchased at steep discount
Neil Woodford stigma helped Hambro Perks swipe portfolio of 16 unlisted stocks earlier this year
-
Leigh Day to issue proceedings in High Court against Link over Woodford collapse
ACD ‘vigorously defending’ claim it mismanaged Neil Woodford’s former fund
